Abstract 4696
Background
Symptom burden and reduced quality of life are considerable hurdles in cancer treatment. The Patient-Reported Outcomes Measurement Information System (PROMIS) assesses physical and psychosocial functional status in clinical and research settings. We use PROMIS scores to establish mean symptom burden within a breast cancer patient population, identifying how subgroups compare to one another, examining potential drivers, and characterizing severe symptom burden between subgroups.
Methods
New cancer patients at the UCSF Breast Care Center (BCC) receive electronic intake questionnaires assessing demographics, health history, and 8 PROMIS domains: depression, anxiety, fatigue, sleep-related impairment and disturbance, cognitive function, applied cognition and physical function. Patients were separated by age and stage of cancer and mean PROMIS reference values for each group were calculated using the NCI’s Health Measures scoring system. We computed enrichment of higher levels of anxiety, sleep impairment, fatigue, physical function impairment, and cognitive decline in metastatic patients versus all other cases.
Results
Compared to stage 0-III, BCC stage IV patients had lower mean values for all assessed domains (p < 0.05). Within the stage IV population, high levels of anxiety were uniquely predictive of low functional status in 6 out of the other 7 domains. The stage IV population was significantly enriched for severe symptomatology in all domains except sleep-related impairment and disturbance when compared to the stage 0-III population.
Conclusions
PROMIS scores indicate that stage IV patients have impaired quality of life in multiple domains. Reference values for demographic groups provide improved guidance in tailoring supportive care referrals. Anxiety emerged as one of the biggest drivers of impairment of other physical, mental, and social functions and thus increased priority addressing anxiety early will likely correspond with improved symptom burden. Our analysis on quality of life will also help determine appropriate thresholds of intervention to trigger referrals and manage a patient’s quality-of-life trajectory more systematically.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Athena Breast Health Network.
Funding
Athena Breast Health Network, University of California, San Francisco.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5489 - Local immune status in cancer cell nests can be a predictor of survival for rectal cancer with neoadjuvant radiotherapy
Presenter: xijin lin
Session: Poster Display session 2
Resources:
Abstract
1653 - Impact of concomitant medications on disease free survival (DFS) and overall survival (OS) in patients from the PETACC8 study.
Presenter: Clémence Brun
Session: Poster Display session 2
Resources:
Abstract
5206 - Updated results of NORDIC 8, a randomised trial of cetuximab every 2 weeks with FOLFIRI or cetuximab with alternating FOLFIRI/FOLFOX in patients with RAS and BRAF wild type metastatic colorectal cancer.
Presenter: Per Pfeiffer
Session: Poster Display session 2
Resources:
Abstract
2992 - Clinical impact of mucinous and poorly differentiated tumors on the outcome of patients with stage II colon cancer: a TOSCA subgroup analysis
Presenter: Gerardo Rosati
Session: Poster Display session 2
Resources:
Abstract
4753 - Exercise improved adjuvant treatment completion rates and treatment-related toxicities in colorectal cancer: A prospective pilot study
Presenter: Hong Jun Kim
Session: Poster Display session 2
Resources:
Abstract
2735 - Bevacizumab plus Oxaliplatin-Based Chemotherapy as Adjuvant Treatment for Colon Cancer (CC): Updated analysis of stage II disease from the AVANT Phase III Randomized trial by the GERCOR Group
Presenter: Aimery De Gramont
Session: Poster Display session 2
Resources:
Abstract
1843 - Multicenter Validation of the Postoperative Carcinoembryonic Antigen Combined Prognostic Model for Stage Ⅲ Colon Cancer
Presenter: Ji Zhu
Session: Poster Display session 2
Resources:
Abstract
2554 - Impact of the IDEA study on clinical practice for stage III colon cancer patients: a French GERCOR - FFCD - GI UNICANCER national survey.
Presenter: Kaissa Ouali
Session: Poster Display session 2
Resources:
Abstract
3285 - Sex hormones and sperm parameters after adjuvant oxaliplatin-based treatment for colorectal cancer
Presenter: Philip Falk
Session: Poster Display session 2
Resources:
Abstract
3905 - Loss of CDX-2 expression is an independent poor prognostic biomarker in colorectal cancer
Presenter: Krittiya Korphaisarn
Session: Poster Display session 2
Resources:
Abstract